SIGNIFICANCEThis study showed that biologic agents alter the competence of the host immune-surveillance system to combat hepatitis virus infections and hepatitis B virus (HBV) or hepatitis C virus (HCV). Reactivation can occur in patients with psoriasis with concurrent HBV or HCV treated with secukinumab, an anti-interleukin 17 agent. The risk of virus reactivation varied in patients with psoriasis with different virological profiles. It is advisable to monitor the viral load/ serum transaminase level and consider antiviral prophylaxis for all hepatitis B surface antigen-positive patients with psoriasis who are being treated with secukinumab.
Localized cutaneous nodular amyloidosis (LCNA) is the rarest type of cutaneous amyloidosis. Typically presenting as waxy nodules on the lower extremities, it demonstrates localized deposition of AL-type amyloid in immunohistologic study and is often associated with focal plasma cell proliferation. Sjögren syndrome, an autoimmune lymphoproliferative disorder, is characterized by keratoconjunctivitis sicca and xerostomia with lymphocytic infiltration of exocrine glands. As shown in case reports, the association of LCNA with Sjögren syndrome is considerable. Herein, we report a 78-year-old woman with LCNA, who was further surveyed and diagnosed with Sjögren syndrome. In light of the significant relation between these 2 diseases, further examination for coexistence of Sjögren syndrome in addition to systemic amyloidosis is well warranted. Prompt identification of an underlying Sjögren syndrome in LCNA with polyclonal immunoglobulin amyloid may have important therapeutic consequences.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.